Optimizing CIDP Management: Integrating Complement Pathway Inhibitors and Advanced Diagnostic Techniques

Prolonged corticosteroid exposure comes at a cost for patients with ITP and wAIHA. Drs. Kuter and Panch review corticosteroid-sparing options and the emerging therapies, from BTK and FcRn inhibitors to CD38-targeted antibodies, that are changing how refractory autoimmune cytopenias are managed. 

Target Audience

Healthcare Professionals

Learning Objectives

By completing this eLearning module:

  • Clinicians will gain diagnostic knowledge and greater competence for early recognition and referral for CIDP. (Moore’s levels 3 and 4)
  • HCPs will gain confidence in using advanced diagnostic techniques and comprehensive testing for accurate CIDP diagnosis. (Moore’s level 4)
  • Clinicians will be able to utilize their enhanced understanding of the role of the immune system and the relevant pathways underlying CIDP to effectively plan personalized treatment approaches for patients. (Moore’s level 4)
  • HCPs will advance their understanding of personalized treatment strategies and emerging therapies like complement pathway inhibitors for CIDP. (Moore’s level 3)

Activity Disclosures

This activity is supported by an educational grant from Sanofi.

Course summary

Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
Course opens: 
12/03/2025
Course expires: 
12/02/2028
Cost:
$0.00
Prof. Jeffrey Allen, MD

Prof. Jeffrey Allen, MD

Professor of Neurology, Department of Neurology, University of Minnesota Medical School, Minneapolis, MN, USA

Prof. Jeffrey Allen, MD discloses the following: Honoraria, consultation fees, advisory board from Alexion, Alnylam, Akcea therapeutics, Argenx SE, Annexon,Dianthus, CSL Behring, Hansa, Grifols, Immunovant, Immunopharm, ImmunoAbs, Sanofi, Johnson & Johnson, Pfizer, Takeda

Prof. Karissa Gable, MD

Prof. Karissa Gable, MD

Professor of Neurology, Division of Neuromuscular Medicine, Duke University School of Medicine, Durham, NC, USA

Prof. Karissa Gable, MD discloses the following: Consultant/Advisor to Argenx, Takeda, Sanofi, CS Behring, Immunovant, Grifols, Dianthus

Prof. Richard Lewis, MD

Prof. Richard Lewis, MD

Professor of Neurology and Director, Electromyography Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Prof. Richard Lewis, MD discloses the following: Consultant/Advisory Boards; Adjudication Committee: Alexion [CIDP; MMN];Amgen (CIDP); Annexon [GBS, CIDP];Argenx [CIDP]; Avilar (anti- MAG); BioCryst (CIDP) CSL Behring [CIDP]; Dianthus [CIDP, MG]; Grifols [CIDP, MMN];Immunovant (CIDP, MMN); J&J [CIDP]; Nervosave (CMT); Nuvig (CIDP); Sanofi [GBS, CIDP, MMN]; Seismic (Anti-MAG);Takeda [CIDP]. TGTX (CIDP); DSMB Boehringer Ingleheim; Intellia (TTR); Cartesian (MG)- chair; MAB: GBS-CIDP FoundationInternational; Speaker: Medscape; Royalties: Up to Date (CIDP)

John Wiley & Sons, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

John Wiley and Sons, Inc. designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. For information on applicability and acceptance of continuing medical education credit for this activity, please consult your professional licensing board.

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™

Price

Cost:
$0.00
Please login or register to take this course.